Bayer presented comprehensive findings from the Phase III ARANOTE trial at the European Society for Medical Oncology (ESMO) Congress 2024, revealing that darolutamide, when combined with androgen deprivation therapy (ADT), significantly improves outcomes for patients with metastatic hormone-sensitive prostate cancer (mHSPC). The ARANOTE trial compared the efficacy of darolutamide plus ADT to ADT alone in mHSPC patients.
The ARANOTE trial is a randomized, controlled, Phase 3 study designed to evaluate the efficacy and safety of darolutamide in combination with ADT compared to ADT alone in patients with mHSPC. The study's primary endpoint was to assess the improvement in overall survival. Secondary endpoints included assessments of radiographic progression-free survival, time to castration resistance, and safety.
Dr. Dayanand Sharma presented the design of the ARANOTE trial, emphasizing the critical need for improved treatment options for mHSPC. The trial enrolled patients with mHSPC and randomized them to receive either darolutamide plus ADT or ADT alone. The results presented at ESMO 2024 highlighted a statistically significant improvement in the primary endpoint with the darolutamide combination.
The findings from the ARANOTE trial suggest that darolutamide plus ADT could become a new standard of care for patients with mHSPC, offering a significant survival benefit over ADT alone. Further details from the trial, including specific hazard ratios and confidence intervals, are expected to be published in a peer-reviewed journal.
